322 related articles for article (PubMed ID: 35693589)
21. Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic Review.
Brouns A; Dursun S; Bootsma G; Dingemans AC; Hendriks L
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34201833
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression.
Sutcliffe P; Connock M; Shyangdan D; Court R; Kandala NB; Clarke A
Health Technol Assess; 2013 Sep; 17(42):1-274. PubMed ID: 24070110
[TBL] [Abstract][Full Text] [Related]
23. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
24. Targeted treatments of bone metastases in patients with lung cancer.
Hirsh V
Front Oncol; 2014; 4():146. PubMed ID: 24982847
[TBL] [Abstract][Full Text] [Related]
25. Bone-modifying agents for non-small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review.
Kim J; Jeong C; Lee J; Ha J; Baek KH; Kim S; An TJ; Park CK; Yoon HK; Lim JU
Semin Oncol; 2023; 50(3-5):105-112. PubMed ID: 37723018
[TBL] [Abstract][Full Text] [Related]
26. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Hu Z; Tian Y; Li W; Ruan Y; Zeng F
Support Care Cancer; 2020 Jul; 28(7):3291-3301. PubMed ID: 31754835
[TBL] [Abstract][Full Text] [Related]
28. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
30. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
31. Analysis of denosumab on skeletal-related events in patients with advanced breast cancer.
Bink KF
Clin J Oncol Nurs; 2015 Oct; 19(5):E108-14. PubMed ID: 26414586
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing.
Campbell-Baird C; Harrelson S; Frey G; Balakumaran A
Support Care Cancer; 2015 Dec; 23(12):3625-32. PubMed ID: 26298333
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
34. The incidence and clinical impact of bone metastases in non-small cell lung cancer.
Kuchuk M; Kuchuk I; Sabri E; Hutton B; Clemons M; Wheatley-Price P
Lung Cancer; 2015 Aug; 89(2):197-202. PubMed ID: 26003503
[TBL] [Abstract][Full Text] [Related]
35. Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice.
Li BT; Wong MH; Pavlakis N
J Clin Med; 2014 Jan; 3(1):1-24. PubMed ID: 26237249
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
Peters S; Danson S; Hasan B; Dafni U; Reinmuth N; Majem M; Tournoy KG; Mark MT; Pless M; Cobo M; Rodriguez-Abreu D; Falchero L; Moran T; Ortega Granados AL; Monnet I; Mohorcic K; Sureda BM; Betticher D; Demedts I; Macias JA; Cuffe S; Luciani A; Sanchez JG; Curioni-Fontecedro A; Gautschi O; Price G; Coate L; von Moos R; Zielinski C; Provencio M; Menis J; Ruepp B; Pochesci A; Roschitzki-Voser H; Besse B; Rabaglio M; O'Brien MER; Stahel RA
J Thorac Oncol; 2020 Oct; 15(10):1647-1656. PubMed ID: 32565388
[TBL] [Abstract][Full Text] [Related]
39. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract][Full Text] [Related]
40. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
